Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography

Heart

Volumn 100, Issue 2, 2014, Pages 153-159

  Cassese, Salvatore ^a   Byrne, Robert A ^a   Tada, Tomohisa ^a   Pinieck, Susanne ^a   Joner, Michael ^a   Ibrahim, Tareq ^b   King, Lamin A ^a   Fusaro, Massimiliano ^a   Laugwitz, Karl Ludwig ^b,c   Kastrati, Adnan ^a,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; PACLITAXEL; PROBUCOL; RAPAMYCIN; ZOTAROLIMUS;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; BARE METAL STENT; BLOOD VESSEL DIAMETER; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DISEASE SURVEILLANCE; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTENOSIS; TREATMENT RESPONSE;

EID: 84891826804     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2013-304933     Document Type: Article

References (40)

1. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370: 937-48. (Pubitemid 47393576)
2. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356: 1030-9. (Pubitemid 46376803)
3. Kirtane AJ, Gupta A, Iyengar S, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009;119: 3198-206.
4. Byrne RA, Sarafoff N, Kastrati A, et al. Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment. Drug Saf 2009;32: 749-70.
5. Dangas GD, Claessen BE, Caixeta A, et al. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol 2010;56: 1897-907.
6. Kastrati A, Byrne R. New roads, new ruts: lessons from drug-eluting stent restenosis. JACC Cardiovasc Interv 2011;4: 165-7.
7. Mauri L, Orav EJ, Kuntz RE. Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation 2005;111: 3435-42. (Pubitemid 40923397)
8. Moreno R, Fernandez C, Sanchez-Recalde A, et al. Clinical impact of in-stent late loss after drug-eluting coronary stent implantation. Eur Heart J 2007;28: 1583-91. (Pubitemid 47227108)
9. Pocock SJ, Lansky AJ, Mehran R, et al. Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. J Am Coll Cardiol 2008;51: 23-32.
10. Brener SJ, Prasad AJ, Khan Z, et al. The relationship between late lumen loss and restenosis among various drug-eluting stents: a systematic review and meta-regression analysis of randomized clinical trials. Atherosclerosis 2011;214: 158-62.
11. Holmes DR Jr, Savage M, LaBlanche JM, et al. Results of prevention of REStenosis with Tranilast and its outcomes (PRESTO) trial. Circulation 2002;106: 1243-50. (Pubitemid 34988643)
12. Lemos PA, Hoye A, Goedhart D, et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study. Circulation 2004;109: 1366-70. (Pubitemid 38387822)
13. Kastrati A, Dibra A, Mehilli J, et al. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation 2006;113: 2293-300. (Pubitemid 43947975)
14. Rathore S, Terashima M, Katoh O, et al. Predictors of angiographic restenosis after drug eluting stents in the coronary arteries: contemporary practice in real world patients. EuroIntervention 2009;5: 349-54.
15. Ellis SG, Vandormael MG, Cowley MJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation 1990;82: 1193-202.
16. Kastrati A, Schomig A, Elezi S, et al. Prognostic value of the modified American College of Cardiology/American Heart Association stenosis morphology classification for long-term angiographic and clinical outcome after coronary stent placement. Circulation 1999;100: 1285-90. (Pubitemid 29440120)
17. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988;44: 1049-60. (Pubitemid 19026037)
18. Carey VJ, Lumley T, Ripley BD. Gee: Generalized Estimation Equation Solver 2008. http://CRANR-projectorg/package=gee (accessed 30 Nov 2012).
19. Gould KL, Lipscomb K, Hamilton GW. Physiologic basis for assessing critical coronary stenosis. Instantaneous flow response and regional distribution during coronary hyperemia as measures of coronary flow reserve. Am J Cardiol 1974;33: 87-94.
20. Eeckhout E, Serruys PW, Wijns W, et al. Percutaneous Interventional Cardiovascular Medicine: the PCR - EAPCI Textbook. Europa Ed. 2012.
21. Mauri L, Orav EJ, Candia SC, et al. Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials. Circulation 2005;112: 2833-9. (Pubitemid 41641678)
22. Beohar N, Davidson CJ, Kip KE, et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 2007;297: 1992-2000. (Pubitemid 46740351)
23. Kastrati A, Schömig A, Elezi S, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997;30: 1428-36. (Pubitemid 27486458)
24. Bauters C, Hubert E, Prat A, et al. Predictors of restenosis after coronary stent implantation. J Am Coll Cardiol 1998;31: 1291-8. (Pubitemid 28219119)
25. Hoffmann R, Mintz GS. Coronary in-stent restenosis - predictors, treatment and prevention. Eur Heart J 2000;21: 1739-49.
26. Jukema JW, Verschuren JJ, Ahmed TA, et al. Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat Rev Cardiol 2012;9: 53-62.
27. Elezi S, Dibra A, Mehilli J, et al. Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents. J Am Coll Cardiol 2006;48: 1304-9. (Pubitemid 44436820)
28. Byrne RA, Kastrati A. Lesions in small coronary vessels disease: should drug-coated balloons replace drug-eluting stents as the treatment of choice? EuroIntervention 2011;7(Suppl K):K47-52.
29. Billinger M, Raber L, Hitz S, et al. Long-term clinical and angiographic outcomes of diabetic patients after revascularization with early generation drug-eluting stents. Am Heart J 2012;163:876-86 e2.
30. Rogers C, Edelman ER. Pushing drug-eluting stents into uncharted territory: simpler than you think-more complex than you imagine. Circulation 2006;113: 2262-5. (Pubitemid 43947969)
31. Berenguer A, Mainar V, Bordes P, et al. Incidence and predictors of restenosis after sirolimus-eluting stent implantation in high-risk patients. Am Heart J 2005;150: 536-42. (Pubitemid 41317626)
32. Iijima R, Ndrepepa G, Mehilli J, et al. Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era. Am Heart J 2007;154: 688-93. (Pubitemid 47440084)
33. Roy P, Okabe T, Pinto Slottow TL, et al. Correlates of clinical restenosis following intracoronary implantation of drug-eluting stents. Am J Cardiol 2007;100: 965-9. (Pubitemid 47368105)
34. Kastrati A, Massberg S, Ndrepepa G. Is diabetes the Achilles' heel of limus-eluting stents? Circulation 2011;124: 869-72.
35. Caixeta A, Lansky AJ, Serruys PW, et al. Clinical follow-up 3 years after everolimusand paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials. JACC Cardiovasc Interv 2010;3: 1220-8.
36. de Waha A, Cassese S, Park DW, et al. Everolimus-eluting versus sirolimus-eluting stents: an updated meta-analysis of randomized trials. Clin Res Cardiol 2012;101: 461-7.
37. Stefanini GG, Byrne RA, Serruys PW, et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J 2012;33: 1214-22.
38. Bangalore S, Kumar S, Fusaro M, et al. Short and long-term outcomes with drug eluting and bare metal coronary stents: a mixed treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 2012;125: 2873-91.
39. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 2009;338:b2393.
40. Kuntz RE, Safian RD, Carrozza JP, et al. The importance of acute luminal diameter in determining restenosis after coronary atherectomy or stenting. Circulation 1992;86: 1827-35.